Alopexx, Inc.
http://www.alopexx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Alopexx, Inc.
Finance Watch: Perlmutter’s Eikon Raises $106m, In-Licenses Pipeline Programs
Private Company Edition: Former Merck R&D head Roger Perlmutter and his new team have accessed drug candidates in oncology and neurodegenerative diseases from three companies, along with new funding. Also, Carmot raised $150m in series E equity and BenchSci brought in $70m.
Deal Watch: Lilly, AbCellera Partner To Attempt Rapid COVID-19 Antibody Development
Partnership will combine AbCellera’s screening of antibodies to the virus with Lilly’s development, commercial capabilities. Vir adds Biogen tie-up to its ongoing coronavirus efforts.
Financings Of The Fortnight Puts On The Weight
Plus news on recent financing activity by Vivus, Aragon, 4s3 Bioscience and Amicus.
Start-Up Quarterly Statistics, Q4 2009
Highlights from the Q4 2009 review of start-up dealmaking: Fundraising in the biopharma, medical device, and in vitro diagnostics industries totaled $976 million, an 88% increase from the previous quarter, and a 77% jump from Q4 2008's $551 million. Of the total fundraising, 66% or $640 million went to the biopharma industry. Compared with Q3 2009, device fundraising rose by 85% (from $113 million to $209 million) and diagnostics companies raised 72% more (from $74 million to $127 million). The fourth quarter of 2009 saw eight acquisitions, all of them in the biopharma industry. Big Pharmas were busy signing deals with start-ups--Sanofi-Aventis inked three while Roche and Novartis AG each signed two.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Alopexx Enterprises, LLC
- Alopexx Vaccine, LLC
- Alopexx Pharmaceuticals, LLC
- Alopexx Oncology LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice